

Genetic diversity and genotype multiplicity of *Plasmodium falciparum* infection in patients with uncomplicated malaria in Chewaka district, Ethiopia

Abdulhakim Abamecha (✉ abdulhakimabamecha@gmail.com)

Jimma University

Hassan El-Abid

Universite Moulay Ismail

Daniel Yilma

Jimma University College of Public Health and Medical Sciences

Wondimagegn Addisu

Jimma University College of Public Health and Medical Sciences

Achim Ibenthal

Hochschule für angewandte Wissenschaft und Kunst Hildesheim Holzminen Gottingen

Abebe Genetu Bayih

Armauer Hansen Research Institute

Harald Noedl

malaria research initiative Bandarban, AUSTRIA

Delenasaw Yewhalaw

Jimma University College of Public Health and Medical Sciences

Mohieddine Mourni

Universite Moulay Ismail

Alemseged Abdissa

Armauer Hansen Research Institute

Research

Keywords: Genetic diversity, Multiplicity of infection (MOI), Plasmodium falciparum, Ethiopia

Posted Date: May 13th, 2020

DOI: <https://doi.org/10.21203/rs.2.24526/v2>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Malaria Journal on June 8th, 2020. See the published version at <https://doi.org/10.1186/s12936-020-03278-6>.

Abstract

Background: Genetic diversity in *Plasmodium falciparum* poses a major threat to malaria control and elimination interventions. Characterization of the genetic diversity of *Plasmodium falciparum* strains can be used to assess intensity of parasite transmission and identify potential deficiencies in malaria control programmes, which provides vital information to evaluating malaria elimination efforts. In this study, we investigated the *P. falciparum* genetic diversity and genotype multiplicity of infection in parasite isolates from cases with uncomplicated *P. falciparum* malaria in Southwest Ethiopia.

Methods: A total of 80 *P. falciparum* microscopy and qPCR positive blood samples were collected from study participants aged six months to sixty years, who visited the health facilities during study evaluating the efficacy of arthemeter-lumefantrine from September-December, 2017. Polymorphic regions of the *msp-1* and *msp-2* were genotyped by nested polymerase chain reactions (nPCR) followed by gel electrophoresis for fragment analysis.

Results: Of 80 qPCR-positive samples analyzed for polymorphisms on *msp-1* and *msp-2* genes, the efficiency of *msp-1* and *msp-2* gene amplification reactions with family-specific primers were 95 % and 98.8%, respectively. Allelic variation of 90% (72/80) for *msp-1* and 86.2% (69/80) for *msp-2* were observed. K1 was the predominant *msp-1* allelic family detected in 20.8% (15/72) of the samples followed by MAD20 and RO33. Within *msp-2*, allelic family FC27 showed a higher frequency (26.1%) compared to IC/3D7 (15.9%). Ten different alleles were observed in *msp-1* with 6 alleles for K1, 3 alleles for MAD20 and 1 allele for RO33. In *msp-2*, 19 individual alleles were detected with 10 alleles for FC27 and 9 alleles for 3D7. Eighty percent (80%) of isolates had multiple genotypes and the overall mean multiplicity of infection was 3.2 (95% CI: 2.87- 3.46). The heterozygosity indices were 0.43 and 0.85 for *msp-1* and *msp-2*, respectively. There was no significant association between multiplicity of infection and age or parasite density.

Conclusions: The study revealed high levels of genetic diversity and mixed-strain infections of *P. falciparum* populations in Chewaka district, Ethiopia, suggesting that both, endemicity level and malaria transmission remain high and that strengthened control efforts are needed in Ethiopia.

Background

The intensification of malaria control interventions has resulted in its global decline, but it remains a significant public health burden across several malaria-endemic countries [1]. The 2018 global malaria report revealed that the incidence rate of malaria declined by 18% from 2010 to 2017, in the same period, the estimated number of cases dropped from 239 million to 219 million, and the number of deaths from 607,000 to 435,000 [1, 2, 3]. In Ethiopia, the trends in malaria over the past five years have also shown a decline in malaria cases and fewer epidemics [4, 6]. In 2014/2015, Ethiopia reported 2,174,707 malaria cases and 662 reported malaria deaths among all age groups which is a 98% reduction compared to 41,000 estimated deaths in 2006 [4, 6]. Between June 2016 and July 2017, the Ethiopian Health

Management Information System (HMIS) reported a total of 1,755,748 malaria cases and 356 deaths due to malaria [4]. The key interventions which have been contributing to such significant decline includes: introduction of prompt and effective treatment with artemisinin-based combination therapies (ACT s), the distribution and promotion of the use of long-lasting insecticidal nets (LLINs), nationwide coverage of indoor residual spraying (IRS), and environmental management [4, 5, 6]. Ethiopia adopted artemether-lumphantrine (AL) in 2004 as first-line for the treatment of uncomplicated falciparum malaria, LLINs coverage has been scaled up in Ethiopia since 2005, resulting in over 64 million nets distributed by 2014. IRS, including permethrin, bendiocarb propoxur and deltamethrin, pirimiphos-methyl has been used between 2014 – 2020. Although these control measures have resulted in a substantial decrease in malaria infections in Ethiopia, malaria is still endemic, with populations in some areas remaining at high risk of infection. Ethiopia has set a goal to eliminate the disease by 2030 using these interventions [4, 7].

Genetically-distinct malaria parasites in natural populations have an extremely high rate of genetic recombination during the sexual stages in a mosquito host, often resulting in multiple strains being transmitted simultaneously [8]. This diversity hampers development of effective vaccine as it limits the efficacy of protective immunity (i.e., antibody-mediated parasite inhibition) [9]. Highly endemic malaria settings are prone to infections containing multiple *P. falciparum* strains, primarily due to repeated exposure to mosquitoes infected with multiple parasite strains [10]. This genetic diversity of the parasite is one of the main factors responsible for the slow acquisition (several years) of immunity against malaria. Thus, individuals would have to encounter a broad range of circulating parasite populations before they develop an effective anti-malarial immunity [11].

Genetic diversity and multiplicity of *P. falciparum* infections are essential parasite indices that could determine the potential impact on the selection of drug-resistant parasites. Although many polymorphic antigens have been described in several stages of the parasite life cycle, merozoite surface protein 1 and 2 (*msh-1* and *msh-2*) seem to be the most appropriate to distinguish parasite populations [12, 13, 14]. This markers are particularly useful in determining the multiplicity of infection (MOI), a measure of the effectiveness of intervention programmes and also *msh-1* and *msh-2* typing are widely used in anti-malarial drug efficacy trials to distinguishing recrudescence parasites from new infections [15, 16, 17]. Study reports by Jelinek et al. [18] and Meyer et al. [19] showed that increased genetic diversity of circulating malaria parasites in a population increases the potential for the selection of drug resistance.

Declining malaria transmission as a result of scaling-up interventions has been shown to affect the parasite population genetics pattern and population structure of *P. falciparum* [20, 21, 22]. The scale up interventions such as the usage of insecticide-treated bed nets, indoor residual spraying [21, 23] and the introduction of new antimalarial drug regimens [20, 24, 25, 26, 27, 28, 29] to control and treat malaria have been shown to cause the genetic drift and decrease the level of allelic diversity (H_e) and MOI. However, this does not occurred in all settings [20, 21]. In addition, the genetic diversity and population structure studies can be used to monitor the effects of any malaria scale-up interventions, such as the impact of malaria control and elimination programs [30]. Hence, accurate assessment of the parasite's genetic diversity across malaria endemic regions could help plan or develop new control and elimination

strategies. The MOI, which identifies the number of clones within a particular infection, can serve as a measure of the level of malaria transmission as well as identify hotspots [31, 32]. Malaria parasite diversity is distinct in different individuals, populations, transmission settings and seasons within endemic zones and changes with variations in parasite prevalence [33], and has been suggested to be constantly changing [34, 35, 36, 37]. Parasite populations even respond to specific interventions, such as rapid diagnostic tests, human host immune pressure and mosquito vector [38, 39, 40]. The identification of hotspots is important in understanding the epidemiology of *P. falciparum* infections for informed interventions to be implemented [32, 41]. The effect of malaria control interventions on the *P. falciparum* population structure in Ethiopia could not be assessed due to the lack of genetic data and systematic genetic surveillance study. Chewaka district in Southwest Ethiopia experiences frequent epidemic outbreaks of malaria. Parasite genetic diversity and multiplicity of infection studies have also been found to be important in the surveillance of strains circulating in a particular transmission area especially in Southwest Ethiopia because there was so limited information available on the genetic structures of *P. falciparum* [42, 43, 44]. This study was aimed at characterizing the genetic diversity and allele frequencies of *msh-1* and *msh-2* genes of *P. falciparum* isolates from uncomplicated malaria patients in Chewaka district, Southwest Ethiopia.

Methods

Study setting

The study was conducted in Ilu-Harar Health Center, Chewka district, Buno Bedele Zone, Southwest Ethiopia during September-December 2017. Chewaka district is located in Buno Bedele zone, Oromia regional state, Ethiopia about 570 kilometers southwest of Addis Ababa. It is situated in lowland areas of Dhidhesa valley, which lies below 1500m above sea level. The district has 26 administrative kebeles (villages). As in most other areas, malaria transmission in Chewaka follows rainy seasons, with transmission peaking in the months between September and December and between April and May. The main malaria control strategy in the district includes Long-Lasting Insecticidal Nets (LLINs), indoor residual spraying (IRS) and malaria case management with ACTs [4, 7]. In 2017, the FMOH updated the country's malaria risk strata based on malaria annual parasite incidence (API), calculated from micro-plan data from more than 800 districts, classifying areas with malaria transmission risk by API as high (≥ 100 cases/1,000 population/year), moderate (≥ 5 and < 100), low (> 0 and < 5), and malaria-free (~ 0). Chewaka district was classified as mesoendemic/moderate transmission setting [4].

Study population and blood sample collection

A total of 80 *P. falciparum* infected blood spots were collected during a therapeutic efficacy study of arthemeter-lumefantrine (Coartem®), between September and December 2017. The participants were aged between six months and sixty years, were residents within Chewaka area, and had presented to the local health center. Febrile patients with axillary temperatures $\geq 37.5^{\circ}\text{C}$, positive for asexual *P. falciparum*

mono-infection giving written consent were included in the study. Children aged less than six month, pregnant women and individuals suffering from any other diseases were excluded.

After consent was obtained, the blood samples were obtained by finger prick and malaria infection was diagnosed using microscopy and qPCR. Whenever a participant tested positive for asexual *P. falciparum* mono-infection, approximately 50µl of whole blood was spotted onto filter paper (Whatman® 927 mm) and air dried. The blood spots were individually placed into plastic bags with desiccant and transported to the Jimma University Clinical Trial Unit (JU-CTU) and stored at -20 °C for a maximum of three months prior to further analysis.

Extraction of parasite DNA

Genomic DNA was extracted from whole blood using proteinase K-base method (GE Healthcare Illustra Blood Genomic Prep Mini Spin Kit) according to the manufacturer's instructions for qPCR species identification and parasite density determination. For nested PCR, the DNA was extracted from stored dried blood spots collected on enrollment (Day-0) and on any day after day 3 were deemed to have recurrent parasitaemia using Pure Link™ Genomic DNA mini Kit (Invitrogen, USA) according to the manufacturer's instructions. DNA was checked for purity and quantity using Nanodrop spectrophotometer (ND 1,000), and stored at -20 °C until used for PCR amplification and detection.

Quantitative PCR (qPCR) screening for *Plasmodium falciparum*

Primer design genesig (Bio-Rad Laboratories, Inc. Germany) standard Kit for *Plasmodium spp.* genomes was analyzed for the *in vitro* quantification of all *Plasmodium spp.* genomes by targeting the 18S ribosomal RNA (18S) gene according to the protocol of Primer design™ Ltd [45]. Species specific *Plasmodium falciparum* genome was analyzed for *in vitro* quantification of *P. falciparum* genomes by targeting the plasmepsin 4 gene according to the protocol of Primerdesign™ Ltd [46]. Each reaction was performed in duplicate and the cycle threshold number (Ct) was determined as their mean. A sample was considered positive if the fluorescent signal was detected in at least one replicate; conversely, if no signal was detected within 40 cycles, a reaction was considered negative.

Genotyping of *Plasmodium falciparum* isolates

Genotyping of *P. falciparum* isolates was carried out by Nested PCR amplification of the two highly polymorphic regions of *msh-1* (block2) and *msh-2* (block3) genes as reported previously [47, 48]. Primer sequences (Additional file 3: Table 1) and cycling parameters used for amplification of the three allelic families of *msh-1* (K1, MAD20 and R033) and two allelic families of *msh-2* (FC27 and 3D7) have been reported elsewhere [49, 50]. Briefly, in the initial amplification, primer pairs corresponding to conserved

sequences within the polymorphic regions of each gene were included in separate reactions. The product generated in the initial amplification was used as a template in five separate nested PCR reactions. In the nested reaction, separate primer pairs targeted the respective allelic types of *msp-1*(K1, MAD20 and RO33) and *msp-2* (IC/3D7 and FC27), with an amplification mixture containing 250nM of each primer, 2mM of MgCl₂ and 125µM of each dNTPs and 0.4 units Taq DNA polymerase (MyTaq™ DNA Polymerase, Bioline). The cycling conditions in the thermocycler (TECHNE, GENIUS), for initial *msp-1* and *msp-2* PCR were as follows: 5 min at 95 °C, followed by 25 cycles for 1 min at 94 °C, 2 min at 58 °C and 2 min at 72 °C and final extension of 5 min at 72 °C. For *msp-1* and *msp-2* nested PCR, conditions were as follows: 5 min at 95 °C, followed by 30 cycles for 1 min at 95 °C, 2 min at 61 °C and 2 min at 72 °C and final extension of 5 min at 72 °C[49]. The allelic specific positive control 3D7 and DNA free negative controls were included in each set of reactions [49]. Fragment analysis of *msp-1* and *msp-2* amplified products were then performed through electrophoresis on 2% and 3% ethidium bromide-stained agarose gel, respectively, and after migration, the DNA fragments were visualized by UV trans-illumination. A standard curve is then drawn by measuring the distances traveled (in cm) from the well, of the bands of the size marker, according to the mathematical function: $f(x) = y$; where $f(x)$ = the actual distance traveled by the band on the gel; $y = \log_{10}(\text{bp})$. The size of an unknown strip is then determined by plotting the distance traveled on the x-axis, then projection on the coordinate axis to determine the size in base pairs. For individual samples, alleles were identified according to band size (Additional file 2: Figure S1; Additional file 3: Figure S2). We assessed the frequency of the occurrence of each allele in the population. We categorized clones into molecular weight groups differing by 20 bp for clear discrimination from other clones and elimination of errors that would result from estimating the molecular weight on agarose-gels.

Data analysis

The *msp-1* and *msp-2* allele frequencies were expressed as the proportion of samples containing an allelic family compared to the total number of samples that gene was detected in isolates. The detection of one *msp-1* and *msp-2* allele was considered as one parasite genotype. The multiplicity of infection (MOI) was defined as the minimum number of *P. falciparum* genotypes per infected subject and estimated by dividing the number of amplified PCR fragments reflecting the parasite genotypes by the number of positive samples in the same marker [50]. The size of polymorphism in each allelic family was analyzed; assuming that one band represented one amplified PCR fragment derived from a single copy of *P. falciparum msp-1* or *msp-2* genes. Alleles in each family were considered the same if fragment sizes were within 20bp interval [16]. Spearman's rank correlation coefficients were calculated to assess association between multiplicity of infection (MOI) and geometric mean parasite density and age. The heterozygosity index (H_e), which represents the probability of being infected by two parasites with different alleles at a given locus, was calculated by using the Genetic Analysis in Excel toolkit (GenAIEx) [51]. Briefly, the allelic diversity (H_e) for each antigenic markers was calculated based on the allele frequencies, using the formula: $H_e = [n / (n-1)] [(1 - \sum p_i^2)]$, where n is the number of isolates sampled and p_i

is the allele frequency at a given locus. Allelic diversity has a potential range from 0 (no allele diversity) to 1 (all sampled alleles are different) [52]. Student's test was used to compare MOI. The chi-square test or Fisher's exact test was used for proportion comparisons. The p value < 0.05 was chosen as threshold significance for the various statistical tests. All statistical analyses were performed using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA).

Results

Demographic and parasitological data

Of the 80 patients enrolled 57 (71.2%) were males, mean (\pm SD) age of participants was 20.96 (\pm 13.6) years. Participants had asexual parasitaemia ranging from 3,699 to 14,744 parasites/ μ L with a geometric mean of 12,513 parasites/ μ L (95% CI 12,167-12,859). The parasite DNA from the 80 *P. falciparum* samples was analyzed for *msp-1* and *msp-2* genes. The estimated frequency of *msp-1* and *msp-2* gene amplification reactions with family-specific primers was 90% (72/80) and 86.3% (69/80), respectively.

Allelic diversity of *P. falciparum* *msp-1* and *msp-2* genes

Polymorphism analysis was assessed in 80 *P. falciparum* isolates within the allelic families of *msp-1* and *msp-2* with a total of 253 distinct fragments detected. The *msp-1* gene analysis showed 63, 50, 31 fragments belonged to K1 (43.75% of overall detected *msp-1* alleles), MAD20 (34.72%) and RO33 (21.5%) allelic families noted, respectively. The *msp-2* gene analysis showed 58, 51 fragments belonged to FC27 (53.2% of overall detected *msp-2* alleles) and IC/3D7 (46.8%) allelic families noted respectively.

The proportion of K1, MAD20 and RO33 types were 20.8, 4.2, and 4.2%, respectively. The remaining 70.8% (51/72) were polyclonal infections. Among polyclonal infections carrying two allelic types, the frequency of samples with K1/MAD20, K1/RO33, and MAD20/RO33 was 31.9, 5.6, and 5.6%, respectively. Infections with all three allelic types were detected in 29.2% of cases (Table 1).

Allele genotyping demonstrated the highly polymorphic nature (i.e. more alleles) of *P. falciparum* in Chewaka isolates with respect to *msp-1* and *msp-2* (Additional file 1: Figure S1 and Additional file 2: Figure S2). A total of 29 individual with *msp* alleles were identified (10 for *msp-1* and 19 for *msp-2*). Among *msp-1* isolates, six K1 (130-300 bp), three MAD20 (180-220 bp) and one RO33 (150 bp) allelic families were noted.

In *msp-2*, a total of 19 different alleles were identified (Table 2), of which ten alleles belonged to FC27 and nine alleles belonged to IC/3D7. Allele sizes ranged from (260 to 540 bp) for FC27 and (170 to 450 bp) for IC/3D7 allelic families. The frequency of samples with only FC27 and IC/3D7 were 26.1 % (18/69) and 15.9 % (11/69), respectively. Forty of the isolates (58%) carried both *msp-2* allelic families.

Genotype multiplicity of *P. falciparum* infection

Of the 80 positive samples, 64 (80%) harbored more than one parasite genotype identified by the presence of two or more alleles of one or both genes. with the overall mean MOI i.e., parasite clones per sample was 3.2 (95% CI: 2.87- 3.46). When considering *msh-1* and *msh-2* genes separately, the MOI was 2.0 (95% CI: 1.82-2.18) and 1.6 (95% CI: 1.46- 1.70), respectively, while 51/72(70.9%) and 40/66(58%) of isolates contained multi-clonal infection at least with 2 clones, respectively. The heterozygosity index, which represents the probability of being infected by two parasites with different alleles at a given locus, was 0.43 for *msh-1* and 0.85 for *msh-2* loci. No significant correlation between multiplicity of infection and parasite density of patients (Spearman rank correlation = 0.094; p= 0.409) or multiplicity of infection and age (Spearman rank correlation = 0.072; p= 0.528). According to age, and parasite density the MOI was similar between individuals of different age and parasite density with-out significant difference (Table 3).

Discussion

The genetic diversity of *P. falciparum* parasites impacts malaria transmission and malaria control strategies [53]. Genetic structures and population genetics studies of *P. falciparum* may hold the key for effective disease surveillance and control programs especially in Southwest Ethiopia as so far there is very limited information available on the genetic structures of *P. falciparum*. As the country moves towards malaria elimination, understanding the genetic diversity and population structure of the malaria parasite populations in hotspots is crucial to guide monitoring and evaluation of malaria control strategies and antimalarial interventions. The present study provides a detailed assessment of genetic diversity and multiplicity of infection of *P. falciparum* parasites from Chewaka district, Southwest Ethiopia.

In this study, allele-specific PCR typing of the *msh-1* and *msh-2* loci showed considerably diverse and extensive allelic polymorphisms in *P. falciparum* populations in the analyzed samples. However, the number of alleles may have been underestimated due to the limitations of the technique used. Indeed, the numbers of alleles (bands) detected may be underestimated due to sensitivity of the PCR technique used as minor fragments (<50 bp) cannot be detected on the agarose gel and also similar sized fragments may be classified as identical leading to a false impression of similarity. Within allele families, alleles of the same size may have different amino acids motifs [51, 52], which emphasizes the importance of sequencing in future studies to confirm diversity and extensive allelic polymorphisms in the *P. falciparum*. A total of 10 and 15 different alleles for *msh-1* and *msh-2*, respectively, were obtained from the parasite isolates in Chewaka district, Ethiopia. This genetic diversity was consistent with the diversity found in Kolla-Shele area, Southwest Ethiopia (*msh-1*: 11; *msh-2*: 12) in 2015 [42], in Northwest Ethiopia (*msh-1*: 12; *msh-2*: 22) in 2018 [44], and Brazzaville in the Republic of Congo (*msh-1*: 15; *msh-2*: 20) in 2018 [54]. In contrast, a higher diversity (*msh-1*: 26; *msh-2*: 25) was found in Bioko Island, Equatorial Guinea in 2018, even though this area has comparable malaria endemicity patterns [53]. K1 was the predominant allelic family for *msh-1* as also demonstrated in previous studies in Africa, including Southwest Ethiopia

[42], Brazzaville, Republic of Congo [16] and Gabon [55]. However, in studies conducted in Northern Ethiopia [44], Central Sudan [56] and Bioko Island, Equatorial Guinea [53] the MAD-20 allele was found to be predominant. In our study the RO33 family showed no polymorphism with only a single allele (160bp). This is similar to findings in Congo [16]. Allele typing of *msp-2* showed that FC27 was the predominant allelic family as also demonstrated in previous reports from Benin [57] and Central Sudan [56] but in contrast with previous studies in Ethiopia [42] and Brazzaville, Republic of Congo [16]. A variation in the prevalence of alleles between different studies likely reflects the differences in sample population. Thus, it is important to conduct studies that include adequate sample size as well as sampling at different time point within the same region to assess and compare the genetic profile of parasites circulating in endemic areas in an attempt to avoid intra and inter individual variation in the number of parasite genotypes detected in the different episodes of malaria. Besides, methodological differences may also affect the comparability of results. Hence, further investigations with more powerful techniques such as capillary electrophoresis and DNA sequencing are needed to better characterize the malaria parasites in the country.

Multiplicity of infection (MOI), i.e. the number of different *P. falciparum* strains co-infecting a single host, has been shown to be a common feature in most malaria-endemic areas and was reported to vary with age, parasite density, immune status, epidemiological settings and transmission intensity [58, 59, 60, 61]. In this study, we have reported that 80% of the isolates harbored more than one parasite genotype identified by the presence of two or more alleles of one or both genes with the overall mean MOI being 3.2 (95% CI: 2.87- 3.46). The overall MOI value reported in this study was higher than previously reported studies, including Ethiopia (MOI: 1.8 - 2.6) between 2015-2018 [42, 43, 44], Brazzaville, Republic of Congo (MOI: 2.2) [16] in 2011 and Bobo-Dioulasso, Burkina Faso (MOI: 1.95) [62]. But, in contrast to study reported in Bioko Island, Equatorial Guinea (MOI: 5.51) [53] in 2018 and Gabon (MOI: 4.0) [63] in 2018. The difference in MOI can be explained by the differences in intensity of malaria transmission seasons. In this study, samples were collected during the major malaria transmission season of September to December, when malaria transmission is very intense. All year round (seasonal) studies covering major and minor transmission seasons are needed to better understand genetic profiles in this area including a sense on seasonal variations.

The results of this study show that age has no association on multiplicity of infection similar to other studies [42, 44, 50] but in contrast with reports from Brazzaville, Republic of Congo [53] and Central Sudan [56]. Previous studies regarding the variation of MOI over age have suggested that the influence of age on the multiplicity of infection is highly affected by endemicity of malaria [57, 58, 59, 60]. This is probably a reflection of the development of anti-parasite specific immunity [31]. Thus, in holo- or hyperendemic areas, immunity develops faster and at younger age than in areas with less intense transmission [64]. Studies have shown an age-dependent MOI in a village with intense perennial malaria transmission but not in areas where malaria is mesoendemic [50, 59]. Similarly, in this study we did not find significant relation between MOI and the parasite count, similar to reports from previous studies in Ethiopia [42, 44] but in contrast with reports from Bioko Island, Equatorial Guinea [57]. This may have been due to the small number of isolates analysed.

High transmission regions like those in many African countries are commonly characterized by *P. falciparum* populations that are genetically diverse. Antigenic marker genotyping carried out in African regions like Burkina Faso, Sao Tome, Malawi, Uganda and Tanzania have identified *P. falciparum* populations with alleles occurring at a frequency below 10 percent with a very high *He* level of 0.78 to 0.99 [17]. Our results indicate that the genetic diversity values were higher based on heterozygosity index for *msh-2* ($He=0.85$), than for *msh-1* ($He=0.43$), suggesting a large genotype diversity within the *msh-2* locus, which was higher than previously reported from Northwest Ethiopia (*msh-2*: He 0.62) in 2018 [44]. Djibouti, a neighboring country to Ethiopia, an initially moderate level of genetic diversity declined over an 11-year period to the point that the expected heterozygosity reached zero in 2009 consistent with very low diversity [30].

Despite the lack of entomological data from Chewaka district, the number of clones co-infecting a single host can be used as an indicator of the level of malaria transmission or the level of host acquired immunity [58, 65, 66]. Besides, transmission intensity can also be affected by other factors such as vector biting behavior and endemicity [65]. Inferring high transmission intensity from the presence of multi-clonal infections alone has additional limitations including estimates of MOI varying by genotyping method, potential impact from sampling frequency and a non-linear relationship between MOI and transmission intensity [65]. Despite these limitations, infections with multiple clones observed in this study, combined with evidence of high genetic diversity may indicate high transmission intensity in the study area.

Limitations of the study

The limitation of the present study is the small number of isolates analysed, which were collected by passive case detection during a therapeutic efficacy study of artemeter-lumefantrine (Coartem®) in the region. In our study, we did not examine the association between the dominant allelic families and the manifestation of the disease because all samples were collected from uncomplicated malaria patients. Thus, the relationship between malaria severity or clinical symptom and genetic diversity could not be addressed in the present study. The collection of samples throughout the year (not just in high transmission season) would potentially give a better understanding of the true diversity in the region. Despite these limitations, the data from the present study has confirmed the high genetic diversity profile and mixed-strain infections of *P. falciparum* populations in Chewaka district, Ethiopia, potentially reflecting both, the endemicity level as well as the fact that malaria transmission remains high in Southwest, Ethiopia.

Conclusions

The high level of polyclonal infections with *P. falciparum* parasites harboring multiple genotypes and also infections with high MOI study indicate the extensive genetic diversity and complexity of *P. falciparum*

infection in the region. More effort is needed to control malaria transmission and prevent the emergence of resistance alleles in the study area.

Declarations

Acknowledgements

The authors would like to express their appreciation to study participants and their parents or guardians, local health officials and all health personnel involved in the study. Special thanks go to Dr. Aline Lamien-Meda, Kalab Eskinder, Ms. Ikram Es-sbata, Ms. Nada Lafkih, and Mr. Tarik Lakhlifi for their technical assistance and help. Support for the development of the manuscript was provided through Jimma University, DAAD In-Country/In-Region scholarship and MOUNAF Intra-African Mobility Project.

Authors' contributions

AbAb, DaYi, DeYe, AGB, HN, AA conceived and designed the study. AbAb, HE, WA, MM performed the experiments. AbAb analyzed the data and drafted the manuscript. AbAb, HE, WA, AI, DaYi, AGB, DeYe, HN, MM, AA reviewed the manuscript. All authors read and approved the final manuscript.

Availability of data and materials

The data sets generated and /or analyzed during the current study are included within the article and its additional files.

Ethical considerations

The study protocol was approved by the Ethics Review Board of Jimma University. Written informed consent from adult participants and parents/guardians of the study children and assent from children aged less than 18 years was obtained for all participants. If a patient, parent or guardian was illiterate, an impartial witness was used.

Competing interests

The authors declare that they have no competing interests.

Author details

¹School of Medical Laboratory Sciences, Faculty of Health Sciences, Institute of Health, Jimma University, Ethiopia. ²Department of Internal Medicine, Institute of Health, Jimma University, Ethiopia. ³Laboratory of Cellular Genomics and Molecular techniques for investigation, Faculty of Sciences, Moulay Ismail University, Morocco. ⁴Faculty of Science and Art, HAWK University, Gottingen, Germany. ⁵Armauer Hansen Research Institute, Addis Ababa, Ethiopia. ⁶Malaria Research Initiative Bandarban, Austria. ⁷Department of Biomedical, College of Public Health and Medical Science, Mettu

University, Ethiopia. ⁸Tropical and Infectious Diseases Research Center (TIDRC), Jimma University, Jimma, Ethiopia

Funding

This project was supported in part by Jimma University, DAAD In-Country/In-Region scholarship program and MOUNAF Intra-African Mobility Project. The funders had no role in study design.

Consent for publication

All authors have given their consent for publication

References

1. World malaria report 2018. Geneva: World Health Organization; 2018.
2. Bhutta ZA, Sommerfeld J, Lassi ZS, Salam RA, Das JK. Global burden, distribution, and interventions for infectious diseases of poverty. *Infect Dis Poverty*. 2014;3:21.
3. Tusting LS, Willey B, Lucas H, Thompson J, Kafy HT, Smith R, et al. Socioeconomic development as an intervention against malaria: a systematic review and meta-analysis. *Lancet*. 2013; 38:963-72.
4. President's Malaria Initiative Ethiopia. Malaria Operational Plan FY 2019.
5. Ministry of Health. Annual Health Sector Performance Report, 2018. Addis Ababa, 2018.
6. Institute Ethiopia Public Health. Ethiopia National Malaria Indicator Survey 2015. Addis Ababa, 2016.
7. Ministry of Health. National strategic plan for malaria prevention, control and elimination in Ethiopia: 2014-2020. Ministry of Health: Addis Ababa; 2014.
8. Conway DJ, Roper C, Oduola AMJ, Arnot DE, Kremsner PG, Grobusch MP, et al. High recombination rate in natural populations of *Plasmodium falciparum*. *Proc Natl Acad Sci USA*. 1999;96:4506-11
9. Healer J, Murphy V, Hodder AN, Masciantonio R, Gemmill AW, Anders RF, et al. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in *Plasmodium falciparum*. *Mol Microbiol* 2004; 52:159-
10. Das S, Muleba M, Stevenson JC, Pringle JC, Norris DE. Beyond the entomological inoculation rate: Characterizing multiple blood feeding behavior and *Plasmodium falciparum* multiplicity of infection in Anopheles mosquitoes in northern Zambia. *Parasites Vectors* 2017; 10:45.
11. Jeffery GM. Epidemiological significance of repeated infections with homologous and heterologous strains and species of *Plasmodium*. *Bulletin of the World Health Organization*. 1966;35:873.
12. Tanabe K, Sakihama N, Kaneko O, Saito-Ito A, Kimura M. A PCR method for molecular epidemiology of *Plasmodium falciparum* msp-1. *Tokai journal of experimental and clinical medicine*. 1998;23:375-382.
13. Kanunfre, K. A. et al. Differential recognition of *Plasmodium falciparum* merozoite surface protein 2 variants by antibodies from malaria patients in Brazil. *Clinical and diagnostic laboratory*

- immunology 10, 973–976 (2003).
14. Hamid MM, Mohammed SB, El Hassan IM. Genetic diversity of Plasmodium falciparum field isolates in Central Sudan inferred by PCR genotyping of merozoite surface protein 1 and 2. *N Am J Med Sci.* 2013;5:95–101.
 15. Ntouni F, Ngoundou-Landji J, Lekoulou F, Luty A, Deloron P, Ringwald P. Site based study on polymorphism of Plasmodium falciparum msp-1 and msp-2 genes in isolates from two villages in Central Africa. *Parasitology.* 2000;42:197–203..
 16. Mayengue PI, Ndounga M, Malonga FV, Bitemo M, Ntouni F. Genetic polymorphism of merozoite surface protein-1 and merozoite surface protein-2 in Plasmodium falciparum isolates from Brazzaville, Republic of Congo. *Malar J.* 2011; 10:276.
 17. Mwingira F, Nkwengulila G, Schoepflin S, Sumari D, Hans-Peter Beck, Snounou G et al. Plasmodium falciparum msp1, msp2 and glurp allele frequency and diversity in sub-Saharan Africa. *Malar J.* 2011;10:79.
 18. Meyer CG, May J, Arez AP, Gil JP, Do Rosario V. Genetic diversity of Plasmodium falciparum: asexual stages. *Trop Med Int Health.* 2002;7:395–408.
 19. Jelinek T, Kilian AH, Westermeier A, Pröll S, Kabagambe G, Nothdurft HD, et al. Population structure of recrudescing Plasmodium falciparum isolates from western Uganda. *Trop Med Int Health.* 1999; 4:476–80.
 20. Nkhoma SC, Nair S, Al-saai S, Ashley E, McGready R, Phyo AP, et al. Population genetics correlates of declining transmission in human pathogen. *Mol Ecol.* 2013;22:273-85
 21. Daniels R, Chang HH, Séne PD, Park DC, Neafsey DE, Schafner SF, et al. Genetic surveillance detects both clonal and epidemic transmission of malaria following enhanced intervention in Senegal. *PLoS ONE.* 2013;8:e60780
 22. Escalante AA, Ferreira MU, Vinetz JM, Volkman SK, Cui L, Gamboa D, et al. Malaria molecular epidemiology: lessons from the International Centers of Excellence for Malaria Research Network. *Am J Trop Med Hyg.* 2015;93(Suppl 3):79–86.
 23. Gatei W, Gimnig JE, Hawley W, Ter Kuile F, Odero C, Iriemenam NC, et al. Genetic diversity of Plasmodium falciparum parasite by microsatellite markers after scale-up of insecticide-treated bed nets in western Kenya. *Malar J.* 2015; 13 Suppl 1:495.
 24. Chenet SM, Schneider KA, Villegas L, Escalante AA. Local population structure of Plasmodium: impact on malaria control and elimination. *Malar J.* 2012; 11:412.
 25. Chenet SM, Taylor JE, Blair S, Zuluaga L, Escalante AA. Longitudinal analysis of Plasmodium falciparum genetic variation in Turbo, Colombia: implications for malaria control and elimination. *Malar J.* 2015; 14(1):363.
 26. Griffing SM, Mixson-Hayden T, Sridaran S, Alam MT, McCollum AM, Cabezas C, et al. South American Plasmodium falciparum after the malaria eradication era: clonal population expansion and survival of the fittest hybrids. *PloS one.* 2011; 6(9):e23486.

27. Akter J, Thriemer K, Khan WA, Sullivan DJ Jr., Noedl H, Haque R. Genotyping of *Plasmodium falciparum* using antigenic polymorphic markers and to study anti-malarial drug resistance markers in malaria endemic areas of Bangladesh. *Malar J.* 2012; 11:386.
28. Alam MT, de SouzaDK, Vinayak S, Griffing SM, Poe AC, DuahNO, et al. Selective sweeps and genetic lineages of *Plasmodium falciparum* drug-resistant alleles in Ghana. *The Journal of infectious diseases.* 2011; 203(2):220–7.
29. Griffing SM, Viana GM, Mixson-Hayden T, Sridaran S, Alam MT, deOliveira AM, et al. Historical shifts in Brazilian *Plasmodium falciparum* population structure and drug resistance alleles. *PloS one.* 2013; 8 (3):e58984.
30. Khaireh BA, Assefa A, Guessod HH, Basco LK, Khaireh MA, Pascual A, et al. Population genetics analysis during the elimination process of *Plasmodium falciparum* in Djibouti. *Malar J.* 2013; 12:201.
31. Ntoumi F, Contamin H, Rogier C, Bonnefoy S, Trape J-F, Mercereau-PuijalonO. Age-dependent carriage of multiple *Plasmodium falciparum* merozoite surface antigen-2 alleles in asymptomatic malaria infections. *Am J Trop Med Hyg.* 1995; 52:81-8.
32. Karl S, White MT, Milne GJ, Gurarie D, Hay SI, Barry AE, Felger I, Mueller I. Spatial effects on the multiplicity of *Plasmodium falciparum* *PLoS One.* 2016; 11:e0164054.
33. Ouattara A, Laurens MB. Vaccines against malaria. *Clin Infect Dis.* 2014; 60:930-6.
34. Childs LM, Prosper OF. Simulating within-vector generation of the malaria parasite diversity. *PLoS One.* 2017; 12:e0177941
35. Pumpaibool T, Arnathau C, Durand P, Kanchanakhan N, Siripoon N, Suegorn A, Sitthi-amorn C, Renaud F, Harnyuttanakorn P. Genetic diversity and population structure of *Plasmodium falciparum* in Thailand, a low transmission country. *Malar J.* 2009; 8:155.
36. Anderson TJ, Haubold B, Williams JT, Estrada-Franco S JG, Richardson L, Mollinedo R, Bockarie M, Mokili J, Mharakurwa S, French N. Microsatellite markers reveal a spectrum of population structures in the malaria parasite *Plasmodium falciparum*. *Mol Biol Evol.* 2000; 17:1467–82.
37. Machado RL, voa MMP, Calvosa VS, Ferreira MU, Rossit AR, EJd S, Conway DJ. Genetic structure of *Plasmodium falciparum* populations in the Brazilian Amazon region. *J Infect Dis.* 2004; 190:1547-55.
38. Arnott A, Barry AE, Reeder JC. Understanding the population genetics of *Plasmodium vivax* is essential for malaria control and elimination. *Malar J.* 2012; 11:14.
39. Haddad D, Snounou G, Mattei D, Enamorado IG, Figueroa J, Ståhl S, Berzins K. Limited genetic diversity of *Plasmodium falciparum* in field isolates from Honduras. *Am J Trop Med Hyg.* 1999; 60:30-4.
40. Babiker HA, Lines J, Hill WG, Walliker D. Population structure of *Plasmodium falciparum* in villages with different malaria endemicity in East Africa. *Am J Trop Med Hyg.* 1997;56:141-7
41. Mita T, Jombart T. Patterns and dynamics of genetic diversity in *Plasmodium falciparum*: what past human migrations tell us about malaria. *Parasitol Int.* 2015;64:238-43

42. Mohammed H, Mindaye T, Belayneh M, Kassa M, Assefa A, Tadesse M, et al. Genetic diversity of Plasmodium falciparum isolates based on MSP-1 and MSP-2 genes from Kolla-Shele area, Arbaminch Zuria District, south-west Ethiopia. *Malar J.* 2015; 14:73.
43. Mohammed H, Kassa M, Assefa A, Tadesse M, Kebede A. Genetic polymorphism of Merozoite Surface Protein-2 (MSP-2) in Plasmodium falciparum isolates from Pawe District, North West Ethiopia. *PLoS ONE.* 2017;12:e0177559
44. Mohammed H, Kassa M, Kassa M, Mekete K. Assefa A, Taye G, Commons RG. Genetic diversity of the msp-1, msp-2, and glurp genes of Plasmodium falciparum isolates in Northwest Ethiopia. *Malar J.* 2015; 14:73.
45. http://www.genesig.com/assets/files/plasmodium_spp_std.pdf
46. http://www.genesig.com/assets/files/p_falciparum_std.pdf
47. Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, Brown KN, et al. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. *Transactions of the Royal Society of Tropical Medicine and Hygiene.* 1999; 93:369-374.
48. Snounou G. Genotyping of Plasmodium spp. Nested PCR. *Methods in molecular medicine.* 2002; 72:103-116.
49. Recommended Genotyping Procedures (RGPs) to identify parasite populations. Amsterdam: Medicines for Malaria Venture and World Health Organization; 2007.
50. Zwetyenga J, Rogier C, Tall A, Fontenille D, Snounou G, Trape J. No influence of age on infectious complexity and allelic distribution in Plasmodium falciparum infections in Ndiop, a Senegalese village with seasonal, mesoendemic malaria. *American Journal of Tropical Medicine and Hygiene.* 1998; 59:726-35.
51. Peakall R, Smouse PE. GenAlEx 6.5: genetic analysis in Excel. Population genetic software for teaching and research—an update. *Bioinformatics* 2012; 28:2537-2539.
52. Nei M. Estimation of average heterozygosity and genetic distance from a small number of individuals. *Genetics.* 1978; 89:583±90.
53. Chen JT, Li J, Zha GC, Huang G, Huang ZX, Xie DD. Genetic diversity and allele frequencies of Plasmodium falciparum msp1 and msp2 in parasite isolates from Bioko Island, Equatorial Guinea. *Malar J.* 2018; 17:458.
54. Nsg G, Ntoumi F, Vouvongui C, Kobawila SC, Kombo MN, Mouanga A, et al. Plasmodium falciparum merozoite protein-1 genetic diversity and multiplicity of infection in isolates from Congolese children consulting in a pediatric hospital in Brazzaville. *Acta Trop.* 2018; 183:78–83.
55. Bouyou-Akotet MK, M'Bondoukwé NP, Mawili-Mboumba DP. Genetic polymorphism of merozoite surface protein-1 in Plasmodium falciparum isolates from patients with mild to severe malaria in Libreville, Gabon. *Parasite* 2015,22,12
56. Hamid MM, Mohammed SB, El Hassan IM. Genetic diversity of Plasmodium falciparum field isolates in Central Sudan inferred by PCR genotyping of merozoite surface protein 1 and 2. *N Am J Med Sci.* 2013;5:95–101.

57. Ogouye'mi-Hounto A, Gazard DK, Ndam N, Topanou E, Garba O, Elegbe Pet al. Genetic polymorphism of merozoite surface protein-1 and merozoite surface protein-2 in *Plasmodium falciparum* isolates from children in South of Benin. *Parasite*. 2013;20:37.
58. Smith T, Felger I, Tanner M, Beck HP: Premunition in *Plasmodium falciparum* infection: Insights from the epidemiology of multiple infections. *Trans R Soc Trop Med Hyg*. 1999; 93 (Suppl 1): 59-64.
59. Konate L, Zwetyenga J, Rogier C, Bischoff E, Fontenille D, Tall A, et al. Variation of *Plasmodium falciparum* *msp1* block 2 and *msp2* allele prevalence and of infection complexity in two neighbouring Senegalese villages with different transmission conditions. *Trans R Soc Trop Med Hyg*. 1999; 93 (Suppl 1): 21-28.
60. Bendixen M, Msangeni HA, Pedersen BV, Shayo D, Bodker R. Diversity of *Plasmodium falciparum* populations and complexity of infections in relation to transmission intensity and host age: A study from the Usambara mountains, Tanzania. *Trans R Soc Trop Med Hyg*. 2001; 95: 143-148.
61. Franks S, Koram KA, Wagner GE, Tetteh K, McGuinness D, Wheeler JG, et al. Frequent and persistent, asymptomatic *Plasmodium falciparum* infections in African infants, characterized by multilocus genotyping. *J Infect Dis*. 2001;183: 796-804.
62. Somé AF, Bazié T, Zongo I, Yerbanga RS, Nikiéma F, Neya C, Taho LK, Ouédraogo JB. *Plasmodium falciparum* *msp1* and *msp2* genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso. *Parasites & Vectors*. 2018; 11:323
63. Ndong Ngomo JM, M'Bondoukwe NP, Yavo W, Bongho Mavoungou LC, Bouyou-Akotet MK, Mawili-Mboumba DP. Spatial and temporal distribution of *Pfmsp1* and *Pfmsp2* alleles and genetic profile change of *Plasmodium falciparum* populations in Gabon. *Acta Trop*. 2018;178:27–33.
64. Baird JK. Host age as a determinant of naturally acquired immunity to *Plasmodium falciparum*. *Parasitol Today*. 1995;11:105–11.
65. Yavo W, Konaté A, Mawili-Mboumba DP, Kassi FK, Tshibola-Mbuyi ML, Angora EK, et al. Genetic polymorphism of *msp1* and *msp2* in *Plasmodium falciparum* isolates from Côte d'Ivoire versus Gabon. *J Parasitol Res*. 2016;2016:3074803.
66. Khouri RR, Bhattacharyya A, Pattnaik P, Malhotra P, Sharma A. Structural and functional dissection of the adhesive domains of *Plasmodium falciparum* thrombospondin-related anonymous protein (TRAP). *Biochem J*. 2004; 379:815-822.

Tables

Table 1 Genotyping of *P. falciparum* *msp-1* polymorphic region block 2 in malaria patients from Chewaka district, Ethiopia

<i>msp-1</i> , N=72	Frequency (%)	Allele size (bp)	No of alleles	Overall MOI
K1	15(20.8)	130-300	6	2.0
MAD20	3(4.2)	180-220	3	
RO33	3(4.2)	150	1	
K1+MAD20	23(31.9)			
K1+RO33	4(5.6)			
MAD20+RO33	3(4.2)			
K1+MAD20+RO33	21(29.2)			

Key: MOI; multiplicity of infection

Table 2: Genotype of *P. falciparum* *msp-2* polymorphic region block region block 3 in malaria patients from Chewaka district, Ethiopia

<i>msp-2</i> ,N=69	Frequency (%)	Allele size(bp)	No of alleles	Overall MOI
FC27	18(26.1)	260-540	10	1.6
IC/3D7	11(15.9)	170-450	9	
FC27+IC/3D7	40(58.0)			

Table 3 MOI according age and parasite density in malaria patients from Chewaka district, Ethiopia

	MOI		
Age	<i>m</i> sp1	<i>m</i> sp2	<i>m</i> sp-1+ <i>m</i> sp-2
< 5 years	1.75	1.67	3.0
5-15 years	2.00	1.61	3.19
≥15 years	2.02	1.56	3.16
<i>P Value</i>	<i>p</i> > 0.05	<i>p</i> > 0.05	<i>p</i> > 0.05
Parasite density			
<1000	2.50	1.25	3.75
≥10000	1.97	1.60	3.13
<i>P Value</i>	<i>p</i> > 0.05	<i>p</i> > 0.05	<i>p</i> > 0.05

Key: MOI, multiplicity of infection

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [AdditionalfileTableS3.docx](#)
- [AdditionalfileFigureS1.docx](#)
- [AdditionalfileFigureS2.docx](#)